A case of Guillain-Barre syndrome after the second dose of AstraZeneca COVID-19 vaccination

Turk J Phys Med Rehabil. 2022 Jun 1;68(2):295-299. doi: 10.5606/tftrd.2022.9984. eCollection 2022 Jun.

Abstract

Coronavirus disease 2019 (COVID-19) is a novel virus that primarily involves the respiratory system. Due to the COVID-19 pandemic, an extensive vaccination program is underway worldwide. Herein, we present a 68-year-old woman with paresthesia of both hands associated with gait instability, which started three to four days after receiving the second dose of Oxford/AstraZeneca vaccine against the COVID-19 infection. The acute inflammatory demyelinating polyradiculoneuropathy subtype of the Guillain-Barre syndrome, which is the most common subtype, was diagnosed. Regardless of the beneficial effects of the vaccines, this case report aimed to evaluate their severe complications, such as Guillain-Barre syndrome, to reduce their occurrence in the future.

Keywords: AstraZeneca vaccine; COVID-19; Guillain-Barre syndrome.

Publication types

  • Case Reports